Trial · NCT06456515
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall survival (OS) | Up to 2 years | The time from randomization to death |
| Secondary | Objective response rate (ORR) | Up to 2 years | The proportion of patients that respond either partially or fully to therapy |
| Secondary | Progression-free survival (PFS) | Up to 2 years | The time from randomization until first evidence of disease progression or death |
| Secondary | Disease control rate (DCR) | Up to 2 years | Percentage of patients with advanced cancer whose therapeutic intervention has led to a complete response, partial response, or stable disease |
| Secondary | Time to progression (TTP) | Up to 2 years | The time from randomization until first evidence of disease progression |
| Secondary | Health-related quality of life (HRQoL) | Up to 2 years | Assessment of patient quality of life with respect to health status |
| Secondary | Adverse events (AE) | Up to 2 years | Use the Common Terminology Criteria for Adverse Events (CTCAE) v4.0. Grade refers to the severity of the AE. The CTCAE v4.0 assigns Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild AE, Grade 2 Moderate AE, Grade 3 Severe AE, Grade 4 Life-threatening or disabling AE, Grade 5 Death related to AE. Overall incidence of TEAE; * Incidence of grade 3 or higher AE; * Incidence of SAEs; * Incidence of AEs leading to permanent discontinuation; * Incidence of AEs leading to medication suspension or dose adjustment. |
| Secondary | Cancer-related fatigue(CRF) | Up to 2 years | A distressing, persistent, subjective sense of physical, emotional, and/or cognitive tiredness or exhaustion related to cancer and/or cancer treatment that is not proportional to recent activity and interferes with usual functioning, use the Revised Piper Fatigue Scale (RPFS) |
| Secondary | Biomarker | Up to 2 years | Biomarker analysis can be categorized as "non-genetic" (e.g., associated proteins) or "genetically relevant" (e.g., associated RNA or DNA). |
| Secondary | Cmax | Up to 2 years | Based on non-compartmental PK evaluation.Cmax refers to the highest measured drug concentration which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample. Blood samples should be collected within 2 hours before electroacupuncture administration and 1 to 4 hours after electroacupuncture by weeks 2 and 3, and 2 hours before electroacupuncture in cycles 4-6 |
| Secondary | Immune-related adverse event (irAE) | Up to 2 years |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06456515/registered